GlassScriptPhysician profile
John Moser Butler
NPI 1427028430
$8,997.83
in general payments reported to CMS, 2019-2025
25 companies · $388 in 2025
The $388 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,887 · 2020: $1,084 · 2021: $275 · 2022: $506 · 2023: $622 · 2024: $235 · 2025: $388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,245.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $5,398.97 | 2019-2025 | Descovy, Yeztugo |
| Viiv Healthcare Company | $831.25 | 2019-2024 | Cabenuva, Dovato, Apretude |
| Merck Sharp & Dohme LLC | $351.62 | 2019-2021 | |
| Mylan Specialty L.P. | $308.07 | 2019 | |
| Novo Nordisk INC | $235.83 | 2023-2025 | Wegovy |
| Theratechnologies INC. | $224.48 | 2019-2022 | |
| Allergan, INC. | $190.60 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $188.78 | 2020-2021 | |
| Insmed, INC. | $168.46 | 2020-2021 | |
| Madrigal Pharmaceuticals | $147.49 | 2025 | Rezdiffra |
| Emd Serono, INC. | $147.10 | 2019-2025 | Serostim |
| Janssen Products, LP | $123.67 | 2022 | |
| Amgen INC. | $121.86 | 2023 | Evenity |
| Astellas Pharma US INC | $109.34 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $100.21 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tetraphase Pharmaceuticals, INC. | $92.92 | 2019-2020 | |
| Melinta Therapeutics, LLC | $58.62 | 2019-2020 | |
| Cumberland Pharmaceuticals, INC. | $44.63 | 2020 | |
| Pfizer INC. | $38.91 | 2019-2020 | |
| Abbvie INC. | $31.49 | 2021 | |
| Mayne Pharma Commercial LLC | $23.68 | 2019-2020 | |
| Dynavax Technologies Corporation | $21.18 | 2019 | |
| Nabriva Therapeutics, Plc | $14.74 | 2020 | |
| Janssen Biotech, INC. | $12.65 | 2019 | |
| Genentech USA, INC. | $11.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Butler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.